Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review

Moore, Kathleen N.; Pothuri, Bhavana

doi:10.1097/ppo.0000000000000558

Cited by 9PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review

Moore, Kathleen N., Pothuri, Bhavana·2021·The Cancer Journal

DOI 10.1097/ppo.0000000000000558

Open this paper in CoChat — free account

Abstract

ABSTRACT: The emergence of clinical trial data for poly(ADP-ribose) polymerase inhibitors (PARPi), in BRCA-associated ovarian cancer (epithelial ovarian cancer [EOC]) in 2009 (Lancet 2010;376:245-251) unleashed a rapid series of additional asset development and clinical trial activation across all lines of EOC treatment, ultimately leading to 8 new approvals of 3 different PARPi in EOC since 2014. Monotherapy iPARPi were approved as frontline maintenance treatment for all patients with EOC who respond to platinum-based chemotherapy irrespective of biomarker (niraparib) and for BRCA-associated cancers (olaparib) (https://www.azpicentral.com/lynparza_tb/lynparza_tb.pdf#page=1; https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf). Combination of olaparib and bevacizumab was approved as maintenance for patients in response to platinum-based and bevacizumab containing frontline therapy whose tumor is characterized as homologous recombination deficient and as approved test by the Food and Drug Administration, inclusive of BRCA-associated cancers (N Engl J Med 2019;381:2416-2428). Niraparib, olaparib, and rucaparib were also approved as maintenance treatment following response to platinum-based therapy in the recurrent setting irrespective of biomarker (https://www.azpicentral.com/lynparza_tb/lynparza_tb.pdf#page=1; https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf). All 3 PARPi were also approved as treatment in lieu of chemotherapy for patients with BRCA-associated cancers in third line and beyond (https://www.azpicentral.com/lynparza_tb/lynparza_tb.pdf#page=1;https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf) and platinum-sensitive homologous recombination deficient in the fourth line and beyond (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf), as well as the National Comprehensive Cancer Network listed in combination with bevacizumab for treatment of patients with platinum-sensitive recurrent disease (https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Ongoing clinical trials in all lines of treatment are evaluating combinations of therapies to improve efficacy among biomarker negative tumors as well as overcome acquired PARPi resistance due to prior use.

Integrity signals

Registry

Crossref · 10.1097/ppo.0000000000000558

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The use of oral PARPi as maintenance therapy after initial treatment of advanced ovarian cancer has led to unprecedented reductions in cancer recurrence and death.
“The use of oral Poly(ADP-ribose) inhibitors (PARPi) as maintenance therapy after initial treatment of advanced ovarian cancer has led to unprecedented reductions in cancer recurrence and death [1].”
From Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue (2023) · cites this paper as [1]

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · see citing works
Self-citation
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452 · see citing works
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. Q., Mannel, R. S., Homesley, H. D., Fowler, J. M., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,413 · see citing works
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martı́n, A., Pothuri, B., Vergote, I. B., Christensen, R. D., Graybill, W. A. S., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P. J., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,278 · see citing works
Self-citation
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,181 · see citing works
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I. L., Pautier, P., Pignata, S., Pérol, D., González-Martı́n, A., Berger, R., Fujiwara, K., Vergote, I. B., Colombo, N., Maenpaa, J. U., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,072 · see citing works
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,856 · see citing works
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,707 · see citing works
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699 · see citing works
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,437 · see citing works
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · see citing works
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189 · see citing works
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ledermann, J. A., Raja, F. A., Fotopoulou, C., González-Martı́n, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,102 · see citing works
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · see citing works
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 710 · see citing works
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 583 · see citing works
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Konstantinopoulos, P. A., Waggoner, S. E., Vidal, G. A., Mita, M. M., Moroney, J. W., Holloway, R. W., Le, L. V., Sachdev, J. C., Chapman‐Davis, E., Colón‐Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 569 · see citing works
Self-citation
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Tewari, K. S., Burger, R. A., Enserro, D. M., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H. Q., Homesley, H. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01009 · Cited by 487 · see citing works
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30376-x · Cited by 450 · see citing works
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Poveda, A. M., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M. L., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00073-5 · Cited by 426 · see citing works
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Wilson, M. K., Pujade-Lauraine, É., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I. B., Reuß, A., Bacon, M. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw663 · Cited by 291 · see citing works
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Penson, R. T., Villalobos-Valencia, R., Cibula, D., Colombo, N., Leath, C. A., Bidziński, M., Kim, J., Nam, J., Mądry, R., Hernández, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02745 · Cited by 291 · see citing works
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Oza, A. M., Tinker, A. V., Oaknin, A., Shapira‐Frommer, R., McNeish, I. A., Swisher, E. M., Ray-Coquard, I. L., Bell‐McGuinn, K. M., Coleman, R. L., O’Malley, D. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.022 · Cited by 280 · see citing works
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
Quigley, D. A., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R. R., Kim, W. B., Lu, E., Schwartzman, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0146 · Cited by 274 · see citing works
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Mirza, M. R., Lundqvist, E. Å., Birrer, M. J., Christensen, R. D., Nyvang, G.-B., Malander, S., Anttila, M., Werner, T. L., Lund, B., Lindahl, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30515-7 · Cited by 245 · see citing works
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
Walsh, C. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.017 · Cited by 244 · see citing works
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 218 · see citing works
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Bitler, B. G., Watson, Z. L., Brubaker, L. W., & Behbakht, K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.003 · Cited by 218 · see citing works
Safety and dose modification for patients receiving niraparib
Berek, J. S., Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I. B., Rosengarten, O. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy181 · Cited by 188 · see citing works
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Friedlander, M. L., Matulonis, U. A., Gourley, C., du Bois, A., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0271-y · Cited by 185 · see citing works
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 154 · see citing works
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
Konstantinopoulos, P. A., Waggoner, S. E., Vidal, G. A., Mita, M. M., Fleming, G. F., Holloway, R. W., Le, L. V., Sachdev, J. C., Chapman‐Davis, E., Colón‐Otero, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.106 · Cited by 143 · see citing works
Self-citation
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
DiSilvestro, P., Colombo, N., Scambia, G., Kim, B., Oaknin, A., Friedlander, M. L., Lisyanskaya, A. S., Floquet, A., Leary, A. F., Sonke, G. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00799 · Cited by 120 · see citing works
Self-citation
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
Poveda, A. M., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M. L., et al. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000962 · Cited by 69 · see citing works
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
Liu, J. F., Brady, M. F., Matulonis, U. A., Miller, A., Kohn, E. C., Swisher, E. M., Tew, W. P., Cloven, N. G., Muller, C. Y., Bender, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.6003 · Cited by 55 · see citing works
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Fabbro, M., Moore, K. N., Dørum, A., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.12.009 · Cited by 48 · see citing works
Self-citation
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N. G., Fleming, G. F., Hendrickson, A. E. W., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5514 · Cited by 29 · see citing works
Self-citation
Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
Bradley, W. H., Moore, K. N., Colombo, N., et al. (2021) · Gynecologic Oncology · doi:10.1016/s0090-8258(21)00694-6 · Cited by 19 · see citing works
Self-citation
ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Mirza, M. R., Mortensen, C. E., Åvall-Lundqvist, E. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps5607 · Cited by 15 · see citing works
SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).
Lowe, E., Jayawardene, D. A., & Penson, R. T. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps5598 · Cited by 9 · see citing works
A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.
Mirza, M. R., Mortensen, C. E., Christensen, R. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5555 · Cited by 9 · see citing works
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
Oza, A. M., Lisyanskaya, A. S., Феденко, А. А., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.5517 · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
Wright, A. A., Poort, H., Tavormina, A., Schmiege, S. J., Matulonis, U. A., Campos, S. M., Liu, J. F., Slivjak, E. T., Gilmour, A. L., Salinger, J. M., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.020 · Cited by 11 · see citing works

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
Baquero, J. M., Marchena-Perea, E. M., Mirabet, R., Torres-Ruiz, R., Blanco‐Aparicio, C., Rodríguez, S., Helleday, T., Benitéz‐Buelga, C., Benitez, J. J., & Osório, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888810 · Cited by 14 · see citing works
Niraparib (Zejula), A Small Molecule, PARP1/2 Inhibitor for Treating Breast, Ovarian, and Pancreatic Cancers
Ng, R. T. (2022) · doi:10.1002/9781119847281.ch12 · Cited by 2 · see citing works
High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors
Ledermann, J. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-32110-3_12
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Konstantinopoulos, P. A., Barry, W. T., Birrer, M. J., Westin, S. N., Farooq, S., Cadoo, K. A., Whalen, C., Luo, W., Liu, H., Aghajanian, C. A., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct008 · Cited by 5 · see citing works
Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
Kortmann, U., McAlpine, J. N., Xue, H., Guan, J., Ha, G., Tully, S., Shafait, S., Lau, A., Cranston, A. N., O’Connor, M. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1382 · Cited by 70 · see citing works

Authors: Moore, K. N., & Pothuri, B.
Affiliations: OU Health Stephenson Cancer Center (US)
NYU Langone Health (US)
Corresponding author: Moore, Kathleen N.
ORCID: Moore, Kathleen N.
Pothuri, Bhavana
Venue: The Cancer Journal
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2021-11
Volume: 27
Issue: 6
Pages: 432-440
ISSN: 1528-9117 (ISSN-L)
1540-336X
DOI: 10.1097/ppo.0000000000000558
OpenAlex: W4200091008
Cited by: 9
References: 42
Citations by year: 2026: 3 · 2025: 1 · 2023: 1 · 2022: 4
FWCI: 0.15
Type: journal article
Language: en
Open access: closed
Locations: The Cancer Journal (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Keywords: PARP inhibitors, epithelial ovarian cancer, maintenance therapy, homologous recombination deficiency, PARP inhibitor resistance, PARP inhibitor combination therapy, bevacizumab, olaparib, niraparib, rucaparib, PARP inhibitor monotherapy, platinum-based chemotherapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial, Antineoplastic Agents, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks